Baker BROS. Advisors LP raised its holdings in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 145.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 323,105 shares of the company’s stock after purchasing an additional 191,572 shares during the quarter. Baker BROS. Advisors LP owned approximately 1.73% of Praxis Precision Medicines worth $18,591,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. CIBC Asset Management Inc lifted its stake in shares of Praxis Precision Medicines by 29.2% during the 3rd quarter. CIBC Asset Management Inc now owns 248,939 shares of the company’s stock valued at $14,324,000 after buying an additional 56,272 shares in the last quarter. Vanguard Group Inc. raised its holdings in Praxis Precision Medicines by 100.6% during the 1st quarter. Vanguard Group Inc. now owns 744,069 shares of the company’s stock valued at $45,403,000 after acquiring an additional 373,131 shares during the period. Renaissance Technologies LLC lifted its position in shares of Praxis Precision Medicines by 523.2% during the second quarter. Renaissance Technologies LLC now owns 75,433 shares of the company’s stock worth $3,120,000 after acquiring an additional 63,329 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Praxis Precision Medicines by 46.6% in the second quarter. TD Asset Management Inc now owns 51,312 shares of the company’s stock worth $2,122,000 after acquiring an additional 16,312 shares during the period. Finally, Moody Aldrich Partners LLC grew its position in shares of Praxis Precision Medicines by 29.6% in the third quarter. Moody Aldrich Partners LLC now owns 31,605 shares of the company’s stock valued at $1,819,000 after purchasing an additional 7,224 shares in the last quarter. Institutional investors own 67.84% of the company’s stock.
Insider Activity
In other news, General Counsel Alex Nemiroff sold 8,239 shares of the company’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $80.20, for a total value of $660,767.80. Following the completion of the sale, the general counsel now owns 10,301 shares of the company’s stock, valued at approximately $826,140.20. This represents a 44.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lauren Mastrocola sold 5,188 shares of Praxis Precision Medicines stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $81.78, for a total transaction of $424,274.64. Following the completion of the transaction, the insider now owns 5,613 shares in the company, valued at approximately $459,031.14. The trade was a 48.03 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.70% of the company’s stock.
Praxis Precision Medicines Stock Performance
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($2.75) EPS for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.74). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The firm had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.53 million. During the same period in the prior year, the company earned ($2.70) EPS. On average, analysts predict that Praxis Precision Medicines, Inc. will post -10.26 earnings per share for the current year.
Wall Street Analysts Forecast Growth
PRAX has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of Praxis Precision Medicines in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $151.00 price target on shares of Praxis Precision Medicines in a report on Thursday, November 7th. Oppenheimer boosted their price objective on shares of Praxis Precision Medicines from $143.00 to $163.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Guggenheim increased their target price on shares of Praxis Precision Medicines from $155.00 to $170.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, Wedbush raised their price target on shares of Praxis Precision Medicines from $40.00 to $48.00 and gave the company a “neutral” rating in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $146.33.
Read Our Latest Report on PRAX
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Featured Articles
- Five stocks we like better than Praxis Precision Medicines
- Short Selling: How to Short a Stock
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Learn Technical Analysis Skills to Master the Stock Market
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Stock Analyst Ratings and Canadian Analyst Ratings
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding PRAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report).
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.